Danielj Oconnor News Today

B. Riley downgraded shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research report report published on Tuesday, Marketbeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. Several other brokerages have also recently commented […]

Johnson & Johnson agreed to acquire Ambrx Biopharma, which is developing cancer treatments. The biotech was spun out from The Scripps Research Institute in 2003.

PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled

PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled Aging in the United States,...

08.01.2024 - SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) - Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for ... Seite 1

Shares of Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […]

Ambrx Biopharma, Inc. (NASDAQ: AMAM) opened trading Thursday down, on the announcement of its addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 18. “2023 has been a transformational year for Ambrx, ...

Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target […]

Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) CEO Daniel J. O’connor sold 50,012 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $9.82, for a total value of $491,117.84. Following the completion of the sale, the chief executive officer now directly owns […]

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6...